Clinical Investigation of the Safety and Efficacy of Low-temperature Plasma as an Adjuvant Treatment for Mild to Moderate Fungal Keratitis: A Pilot Study

Ocul Immunol Inflamm. 2023 Jul;31(5):881-890. doi: 10.1080/09273948.2022.2060839. Epub 2022 May 6.

Abstract

Purpose: This pilot study assessed the safety and efficacy of low-temperature plasma (LTP) as an adjuvant treatment for mild to moderate fungal keratitis (FK).

Methods: Thirty FK patients were randomized into LTP (n = 15) and control (n = 15) groups. Patients were followed up for 3 months. The best-corrected visual acuity (BCVA), ulcer size, and hypopyon height were measured; healing time or complications were documented and compared.

Results: More patients in the LTP group healed completely (11/15 in 48 days) compared with the control group (4/15 in 59.5 days), and those patients had a deeper initial ulcer depth and exhibited better BCVA improvements. Four patients failed after LTP treatment due to perforation, increased inflammatory infiltration, or hypopyon; those with more hypopyon were more likely to fail.

Conclusions: LTP could be a promising adjuvant therapy to topical antifungal drugs for mild to moderate FK.

Keywords: Adjuvant treatment; efficacy; fungal keratitis; low-temperature plasma; safety.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Antifungal Agents / therapeutic use
  • Corneal Ulcer* / diagnosis
  • Corneal Ulcer* / drug therapy
  • Corneal Ulcer* / microbiology
  • Eye Infections, Fungal* / drug therapy
  • Eye Infections, Fungal* / microbiology
  • Humans
  • Keratitis* / diagnosis
  • Keratitis* / drug therapy
  • Keratitis* / microbiology
  • Pilot Projects
  • Temperature
  • Ulcer / drug therapy

Substances

  • Antifungal Agents